ArticleNature communications2024
Inflammation-free electrochemical in vivo sensing of dopamine with atomic-level engineered antioxidative single-atom catalyst.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Single-Atom-Enhanced Fully Inkjet-Printed Electrochemical Sensor for Dopamine Detection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Galvanically Deposited FeChemistry, an Asian journal · 2026Article
- Application of Single-Atom Nanozymes in the Detection of Small Biomolecules: A Review.Molecules (Basel, Switzerland) · 2026Review
- Chemically Selective Nanoelectrode Arrays for Real-Time, Parallel Neurotransmitter and Electrical Recording.Small science · 2026Article
- In vivo multimodal neurochemical interfaces for real-time decoding of brain circuit.Nature reviews. Neuroscience · 2026Review
- Photocatalytically Activated Cu-NAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Preparation and biomedical applications of single-metal atom catalysts.Nature protocols · 2026Review
- Antioxidant Nanozymes: From Rational Design to Biomedical Applications.Research (Washington, D.C.) · 2026Review
- Recent advances of in situ and in vivo electrochemical analysis of brain chemistry at micro- and nanoscale.QRB discovery · 2026Review
- Multifunctional Hybrid Nanomedicines for Neurodegenerative Diseases: A Paradigm Shift from Rational Design to Clinical Translation.International journal of nanomedicine · 2026Review
- A Dual-Mode Wireless Microsystem for Monitoring Dopamine and Spike Changes with Dexmedetomidine.Cyborg and bionic systems (Washington, D.C.) · 2026Article
- Neural vs Neuromorphic Interfaces: Where Are We Standing?Chemical reviews · 2025Review
- Polymeric Composite-Based Electrochemical Sensing Devices Applied in the Analysis of Monoamine Neurotransmitters.Biosensors · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Electrochemical methods with tissue-implantable microelectrodes provide an excellent platform for real-time monitoring the neurochemical dynamics in vivo due to their superior spatiotemporal resolution and high selectivity and sensitivity. Nevertheless, electrode implantation inevitably damages the brain tissue, upregulates reactive oxygen species level, and triggers neuroinflammatory response, resulting in unreliable quantification of neurochemical events. Herein, we report a multifunctional sensing platform for inflammation-free in vivo analysis with atomic-level engineered Fe single-atom catalyst that functions as both single-atom nanozyme with antioxidative activity and electrode material for dopamine oxidation. Through high-temperature pyrolysis and catalytic performance screening, we fabricate a series of Fe single-atom nanozymes with different coordination configurations and find that the Fe single-atom nanozyme with FeN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.